With a 5-year dividend growth rate of 15.23%, Eli Lilly and Company (NYSE:LLY) is among the 10 Best Dividend Growth Stocks to Buy and Hold for 3 Years. CNBC Reports Strong Phase 3 Results for Eli Lilly’s Retatrutide In a CNBC report published on May 21, Eli Lilly and Company (NYSE:LLY) said its experimental obesity…
Eli Lilly and Company (NYSE:LYLY) is one of the Good stocks to buy now. On March 20, Jefferies reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) with a $1,300 price target. ​The rating is based on the company’s prescribing data for GLP-1 drugs. Oral Wegovy had approximately 89,300 IMS prescriptions and 76,800 Symphony…
Eli Lilly and Company (NYSE:LLY) is included among the The 14 Best GARP Stocks to Buy According to Analysts. RBC Capital Starts Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market On February 25, RBC Capital initiated coverage of Eli Lilly and Company (NYSE:LLY) with an Outperform rating and a $1,250 price target. The firm…
Eli Lilly and Company (NYSE:LLY) is included among the 16 Best Dividend Stocks with Growing Payouts. Eli Lilly (LLY) Expands Portfolio with Clazakizumab Deal, Reuters Reports According to a Reuters report on Feb. 18, Australia’s CSL said it had granted Eli Lilly and Company (NYSE:LLY) certain rights to develop and commercialize clazakizumab, an anti-interleukin-6 monoclonal…
Impax Asset Management’s “Impax US Sustainable Economy Fund” published its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns about elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the benchmark Russell 1000…
